Cover Image


Global Dendritic Cell Cancer Vaccine Market Outlook 2020

出版商 KuicK Research 商品編碼 322277
出版日期 內容資訊 英文 213 Pages
商品交期: 最快1-2個工作天內
Back to Top
樹突狀細胞癌症疫苗市場預測 Global Dendritic Cell Cancer Vaccine Market Outlook 2020
出版日期: 2016年03月01日 內容資訊: 英文 213 Pages



第1章 樹突狀細胞癌症疫苗的生成

第2章 樹突狀細胞的分類

第3章 樹突狀細胞的作用機制

第4章 開發樹突狀細胞生物化學的新疫苗策略

  • CD4 T 細胞的供給 CD8 T 補助細胞
  • 在樹突狀細胞的原位的採用、成熟、裝載
  • NKT細胞活性化策略

第5章 樹突狀細胞癌症疫苗市場及臨床性考察

  • 樹突狀細胞癌症疫苗接種相關趨勢
  • 樹突狀細胞疫苗開發平台概要

第6章 樹突狀細胞癌症疫苗比較分析與同等的疫苗

  • 樹突狀細胞癌症疫苗和單株抗體
  • 樹突狀細胞癌症疫苗和肽為基礎的癌症疫苗
  • 樹突狀細胞癌症疫苗和細胞因子為基礎的的癌症疫苗
  • 樹突狀細胞癌症疫苗和武裝抗體為基礎的癌症疫苗

第7章 樹突狀細胞癌症疫苗的市場促進因素:堅持樹突狀細胞癌症疫苗的理由

第8章 預測:困難的癌症的免疫療法領域的樹突狀細胞癌症疫苗

第9章 結論:樹突狀細胞癌症疫苗-癌症治療的一線光明

第10章 樹突狀細胞癌症疫苗臨床開發平台:各國,各企業,各適應症,各相位

  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段

第11章 上市的樹突狀細胞癌症疫苗

  • CreaVax(腎臟癌的治療用,韓國)

第12章 退出市場的樹突狀細胞癌症疫苗

  • Provenge(Dendreon Corporation)

第13章 臨床試驗開發中止/中斷的樹突狀細胞癌症疫苗

  • 中止
  • 沒有開發報告
  • 中斷

第14章 競爭情形

  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • Bellicum Pharmaceuticals
  • Creagene
  • DanDrit Biotech
  • DCPrime
  • Dendreon Corporation
  • Elios Therapeutics
  • ImmunoCellular Therapeutics
  • Immunicum
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • Glaxo Smith Kline
  • ImmunoCellular Therapeutics
  • Tella Incorporation
  • Theravectys
  • Vaxil BioTherapeutics




Dendritic cell first discovered in the early 19th century by Paul Langerhans and their further study and the role it plays in immune system conducted by M. Steinman in 1973, has only received the must deserved attention as a vaccine molecule, in general and as a cancer therapeutics, in particular in the recent past years. There was a widespread skepticism regarding its potential as a vaccine in the scientific community which only eased out with the further ongoing clinical trials.

However, gone are the gloomy days for the dendritic cells, the sentinels of the immune system, as its market share in cancer market is rising exponentially. Dendritic cell cancer vaccines which started its journey with ex-vivo clinical trials in murine models have now gone on to rephrasing the molecular mechanism of the immune system, enriching our immunological knowledge and empowering our ability to counteract the tumor growth. Dendritic cells have also been successful in generating therapeutic and prophylactic options not just for cancer treatments but also for other ailments, deemed incurable.

Dendritic cells play a critical role in immune modulation, which makes them a perfect target for the clinical studies revolving around T cell induced immune reaction like allergic reaction studies, host v/s graft disease, infection resistance studies and immune-compromised patient studies, besides cancer vaccines development. However, it has been seen that many tumor antigens do not induce T cell mediated immune response which could be due the absence of functional dendritic cells in the tumors. It has been observed that dendritic cells that invade colon and skin cancer cells, sometimes lack CD80 and CD86 epitopes, therefore have limited T-cell stimulatory activity. Besides, tumors are capable of secreting growth factors like interleukin-10, Tumor Growth Factor, which retards the development and the maturation stages of dendritic cells. This implies that with increased dendritic cells invading the tumor cells the probability of enhanced prognosis is greatly increased.

There are several combinational therapies wherein dendritic cells are administered along with monoclonal antibodies, antibody-drug conjugates and peptide based vaccines to increase the efficacy of the vaccines. This is because of the fact that in the cancer patients, the immune system is already compromised, besides the tumor microenvironment which negates the mechanism of action of immunological cells. The role of conventional therapy like chemotherapy, surgical removal of tumor cells or radiotherapy also needs to be underscored as they help in reducing the bulk of tumorous growth. The cancer based vaccines when administered thereafter, is reported to have increased efficiency.

As dendritic cells are found to have a modulatory effect on almost all the parameters of the immune system, all other types of cancer vaccines are found to be administered in conjugation with dendritic cells cancer vaccine to have a synergistic effect on immune system against tumor growth. With further advancement in immunological studies, dendritic cells cancer vaccine will have a driving effect on cancer therapeutics which will have a lion's share on cancer vaccine market.

"Global Dendritic Cell Cancer Vaccine Market Outlook 2020" Report highlights:

  • Introduction & Mechanism of Action of Dendritic Cells
  • New Vaccine Strategies That Exploit Dendritic Cells Biochemistry
  • Dendritic Cell Cancer Vaccine Market & Clinical Insight
  • Comparative Insight of Dendritic Cell Vaccines & Other Class of Vaccines
  • Dendritic Cell Cancer Vaccine Pipeline by Country, Company, Indication & Phase
  • Dendritic Cell Cancer Vaccine Clinical Pipeline: 58 Vaccines
  • Majority in Phase I/II & Phase II Clinical Trials: 12 Vaccines

Table of Contents

1. Dendritic Cells Cancer Vaccine: The Genesis

2. Classification of Dendritic Cells

3. Mechanism of Action of Dendritic Cells

  • 3.1 Antigen Presentation & Induction of Cellular Immune Responses
  • 3.2 Sources of Antigen to Be Loaded Onto Dendritic Cells
  • 3.3 Dendritic Cells Source & Subsets
  • 3.4 Maturational State
  • 3.5 Maturation Stimuli
  • 3.6 Migration
  • 3.7 Route, Dose & Schedule of Dendritic Cells Vaccination
  • 3.8 Clinical Results in Miscellaneous Cancers
  • 3.9 Quality Control
  • 3.10 Immune Monitoring

4. New Vaccine Strategies That Exploit Dendritic Cells Biochemistry

  • 4.1 Provision of CD4 T-Cell Help for CD8 T Cells
  • 4.2 Strategies to Recruit, Mature & Load Dendritic Cells In Situ
  • 4.3 Strategies to Activate NKT Cells

5. Dendritic Cell Cancer Vaccine Market & Clinical Insight

  • 5.1 Some Trends Involving Dendritic Cells Cancer Vaccination
  • 5.2 Dendritic Cell Cancer Vaccine Pipeline Overview

6. A Comparative Insight of Dendritic Cell Vaccines & its Peers

  • 6.1 Dendritic Cell Cancer Vaccine & Monoclonal Antibodies
  • 6.2 Dendritic Cell Cancer Vaccine & Peptide Based Cancer Vaccine
  • 6.3 Dendritic Cell Cancer Vaccine & Cytokine Based Cancer Vaccine
  • 6.4 Dendritic Cell Cancer Vaccine & Antibody Drug Conjugate Based Cancer Vaccine

7. The Growth Factors: Why the Fixation with Dendritic Cell Cancer Vaccines?

8. Road Ahead: Dendritic Cell Cancer Vaccine in the Challenging Horizon of Cancer Immunotherapy

9. Conclusion: Dendritic Cell Cancer Vaccine; a Silver Lining to the Dark Under-Belly of Cancer

10. Dendritic Cell Cancer Vaccine Clinical Pipeline By Country, Company, Indication & Phase

  • 10.1 Research
  • 10.2 Preclinical
  • 10.3 Clinical
  • 10.4 Phase-I
  • 10.5 Phase-I/II
  • 10.6 Phase-II
  • 10.7 Phase-II/III
  • 10.8 Phase-III

11. Marketed Dendritic Cell Cancer Vaccine: CreaVax® ( Renal Cancer, South Korea)

12. Market Withdrawl: Provenge by Dendreon Corporation

13. Discontinued & Suspended Dendritic Cell Cancer Vaccine in Clinical Trials

  • 13.1 Discontinued
  • 13.2 No Development Reported
  • 13.3 Suspended

14. Competitve Landscape

  • 14.1 3M Company
  • 14.2 Activartis
  • 14.3 Argos Therapeutics
  • 14.4 Batavia Bioservices
  • 14.5 Bellicum Pharmaceuticals
  • 14.6 Creagene
  • 14.7 DanDrit Biotech
  • 14.8 DCPrime
  • 14.9 Dendreon Corporation
  • 14.10 Elios Therapeutics
  • 14.11 ImmunoCellular Therapeutics
  • 14.12 Immunicum
  • 14.13 Kiromic
  • 14.14 Medigene
  • 14.15 Merck
  • 14.16 Northwest Biotherapeutics
  • 14.17 Glaxo Smith Kline
  • 14.18 ImmunoCellular Therapeutics
  • 14.19 SOTIO
  • 14.20 Tella Incorporation
  • 14.21 Theravectys
  • 14.22 Vaxil BioTherapeutics
Back to Top